# Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

> **NCT03191097** · PHASE3 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 310 (actual)

## Conditions studied

- Influenza, Human
- Acute Respiratory Infection
- Viral Infection
- Common Cold

## Interventions

- **DRUG:** Ingavirin
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03191097
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-12
- **Final completion:** 2015-03
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2017-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191097, "Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03191097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*